Osteosarcoma in Dogs: Recognising and Treating Canine Bone Cancer

The first sign is almost always a limp. That is the difficult thing about osteosarcoma, the most common malignant bone tumour in dogs: it announces itself in the most ordinary way a dog can announce anything. Most limps are not cancer. Dogs pull things, tread on things and overdo it at the park. But a Morris Animal Foundation white paper on osteosarcoma makes a case worth taking seriously, which is that in the dogs most at risk, a limp that does not resolve deserves an X-ray rather than a fortnight of wait-and-see.

What osteosarcoma is, and where it turns up

Osteosarcoma is cancer arising in bone. The Foundation describes it as the most common type of malignant bone tumour in dogs, and it is not rare: more than 10,000 dogs are diagnosed with it every year in the United States alone. Cornell University's Riney Canine Health Center, which maintains an owner-facing page on the disease, notes that the tumours most often appear in the long bones of the front or back legs, occasionally in the jaw, ribs or pelvis, and that affected dogs are typically around seven years old.

The signs owners actually notice, according to Cornell, are lameness or a reluctance to walk, a firm localised swelling usually on a limb, and muscle loss around the affected area. Bone tumours hurt. Pain control is not an optional extra in this disease, it is a central part of care from the moment of diagnosis, and it is worth raising with your vet in the first conversation rather than the third.

Which dogs are most at risk

This is overwhelmingly a large-dog disease. The Foundation's list of predisposed breeds runs to Rottweilers, golden retrievers, Irish wolfhounds, greyhounds, deerhounds, St Bernards, mastiffs, Doberman pinschers, Great Danes, Irish setters and German shepherds. Cornell's shorter list overlaps heavily with it. If your dog is small, this is a much less likely explanation for a limp.

• A limp in a large or giant breed dog lasting more than a few days is worth imaging rather than rest.
• Firm swelling on a leg, particularly near a joint, should be examined.
• Reluctance to walk, or a dog who suddenly hates stairs, is a pain signal worth reporting.
• Diagnosis usually starts with X-rays; Cornell notes that a biopsy is the only way to confirm it definitively.

What treatment looks like

The standard approach, in the Foundation's summary, is surgery on the primary tumour, either amputation of the affected limb or limb-sparing surgery, followed by chemotherapy. Chemotherapy after surgery can inhibit spread and prolong survival, but it does not cure the disease. That distinction matters when you are weighing up what to put your dog through.

Amputation is the part owners struggle with most, and the reason it is standard deserves saying out loud: the primary tumour is painful, and removing it removes the pain along with the tumour. Cornell lists amputation as the standard surgical approach for limb tumours, with limb-sparing surgery and stereotactic radiation, a highly focused form of radiotherapy, as specialist alternatives. Which route suits a particular dog depends on where the tumour sits, how much bone is involved, and the state of the dog's other joints.

On survival, the two sources agree closely. Cornell gives a median of about nine months with surgery and chemotherapy, and about four months with amputation alone. The Foundation's framing is blunter: eight out of ten dogs die within two years of diagnosis, most live less than a year, fewer than 25% reach two years on conventional therapy, and between 4,000 and 8,000 dogs a year die of the spread rather than of the original tumour.

Why the numbers have not moved

The Foundation is unusually frank about this. Despite thirty years of advances in canine oncology, it reports no notable progress in the treatment and survival of dogs with osteosarcoma. Surgery on the primary tumour got better. The metastasis did not get less lethal. Almost everything in the current research pipeline is aimed squarely at that gap.

Some of it is genuinely interesting. Foundation-funded researchers have studied how osteosarcoma tumours release tiny vesicles, which the paper likens to small cargo bags, into the bloodstream. These carry biologically active genes and proteins, and when they reach somewhere like the lungs they appear to prepare the ground so it is more welcoming to tumour cells arriving later. Interrupt that preparation and you may interrupt the spread. Other funded work found that 42% of canine osteosarcoma tumours carry a mutation in one particular gene, which in humans is associated with more aggressive disease and poorer response to chemotherapy.

Two immunotherapy trials, testing treatments that help the body reprogram its own immune system to attack cancer cells, are underway with Foundation funding, both aimed at slowing or stopping spread, with preliminary results the Foundation describes as promising. Researchers it funds have also developed a simple blood test, still under development, that may one day allow early detection, screening of at-risk dogs and monitoring for relapse during treatment. Nanoparticle drug delivery and choosing chemotherapy by a tumour's gene signature sit further out again.

The children in this story

One detail from the white paper is worth knowing, partly because it places dogs at the centre of something larger. Osteosarcoma in dogs closely resembles osteosarcoma in children, where it is the most common form of bone cancer although rare overall. The Foundation notes it occurs roughly ten times more often in dogs than in children, and that only about 70% of young people diagnosed survive five years. Work that cracks this cancer in dogs may help crack it in children too. That is the whole premise of comparative oncology, and it is a real one.

A last word on tone. These figures are grim and the Foundation does not dress them up. But they describe averages across many thousands of dogs, and individual dogs sit on both sides of an average. Treatment for osteosarcoma is not futile: it reliably removes a source of real pain, and it reliably buys time that is usually good time. What it does not yet do is cure, and the honest research answer to that, for now, is not yet.

This article explains published research and is educational only. It is not a substitute for diagnosis or treatment advice from a licensed veterinarian who has actually examined your dog.